John V. Heymach, MD, PhD, of the MD Anderson Cancer Center, presented results from the trial at AACR 2025.
Lung Cancer
Advertisement
Dr. Le Marchand’s "seminal work has elucidated racial and ethnic disparities in lung cancer risk," officials said.
PALOMA-2 used data from PALOMA-3 to evaluate subcutaneous versus intravenous amivantamab for EGFR-mutated NSCLC.
Dr. Ladanyi reflects on genetic hotspot mutations that have not been previously well characterized in lung adenocarcinoma.
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Final overall survival data from the phase 3 study demonstrated significant benefits for patients with EGFR-mutated aNSCLC.
The study authors evaluated the physical, psychosocial, and lifestyle challenges faced by patients with lung cancer.
Most patients with MPM experience pleural effusion, but questions remain about the condition's impact on patient outcomes.
The NCCN 2025 Annual Conference will be held from March 28-30 in Orlando, Florida.
Expanded treatment options for pleural mesothelioma are "urgently needed," due to the high morbidity of the disease.
The Lung Cancer Screening Registry will evolve into the Early Lung Cancer Detection Registry.
Mara B. Antonoff, MD, FACS, discusses the organization's mission, the resources it offers, and her hopes for the future.
Learn how researchers determined the best treatment strategy for smoking cessation among patients who currently smoke.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.